Menu
Search
|

Menu

Close
X

Aileron Therapeutics Inc ALRN.OQ (NASDAQ Stock Exchange Global Market)

1.93 USD
-- (--)
As of Mar 21
chart
Previous Close 1.93
Open --
Volume --
3m Avg Volume 50,591
Today’s High --
Today’s Low --
52 Week High 9.13
52 Week Low 0.52
Shares Outstanding (mil) 14.71
Market Capitalization (mil) 214.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.664
FY17
-1.539
FY16
-1.237
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
--
13.82
Return on Equity (TTM)
vs sector
--
15.25

EXECUTIVE LEADERSHIP

Jeffrey Bailey
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Manuel Aivado
President, Chief Executive Officer, Director, Since 2018
Salary: $391,065.00
Bonus: $140,000.00
Donald Dougherty
Senior Vice President, Chief Financial Officer, Since 2017
Salary: $194,072.00
Bonus: $105,500.00
D. Allen Annis
Senior Vice President - Research, Since 2018
Salary: --
Bonus: --
Kira Nelson
Vice President - Finance, Vice President - Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

490 Arsenal Way
WATERTOWN   MA   02472-2870

Phone: +1617.9950900

Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.

SPONSORED STORIES